Targovax ASA: Poster at European Society for Medical Oncology (ESMO)
· Describing the role of ONCOS-102 in combination with aPD1 in aPD1 refractory, advanced or unresectable melanoma Oslo, Norway, 16 September 2021 - Targovax ASA (OSE: TRVX), a clinical stage immuno-oncology company developing immune activators to target hard-to-treat solid tumors, today announces that the poster “A pilot study of Engineered Adenovirus ONCOS-102 in combination with pembrolizumab (pembro) in checkpoint inhibitor refractory advanced or unresectable melanoma” is now available at the ESMO congress website and on the Company’s website. The poster will be presented as an e-